• Member Statistics

    • 863,867 Colleagues-to-Date [Sponsored by a generous R&D grant from iMBA, Inc.]
  • ME-P Information & Content Channels

  • ME-P Archives Silo [2006 – 2021]

  • Ann Miller RN MHA [Managing Editor]

    USNews.com, Reuters.com,
    News Alloy.com,
    and Congress.org

    Comprehensive Financial Planning Strategies for Doctors and Advisors: Best Practices from Leading Consultants and Certified Medical Planners(TM)

    Product Details

    Product Details

    Product Details


    New "Self-Directed" Study Option SinceJanuary 1, 2020
  • Most Recent ME-Ps

  • PodiatryPrep.org

    Lower Extremity Trauma
    [Click on Image to Enlarge]

  • ME-P Free Advertising Consultation

    The “Medical Executive-Post” is about connecting doctors, health care executives and modern consulting advisors. It’s about free-enterprise, business, practice, policy, personal financial planning and wealth building capitalism. We have an attitude that’s independent, outspoken, intelligent and so Next-Gen; often edgy, usually controversial. And, our consultants “got fly”, just like U. Read it! Write it! Post it! “Medical Executive-Post”. Call or email us for your FREE advertising and sales consultation TODAY [770.448.0769]

    Product Details

    Product Details

  • Medical & Surgical e-Consent Forms

  • iMBA R&D Services

    Commission a Subject Matter Expert Report [$2500-$9999]January 1, 2020
    Medical Clinic Valuations * Endowment Fund Management * Health Capital Formation * Investment Policy Statement Analysis * Provider Contracting & Negotiations * Marketplace Competition * Revenue Cycle Enhancements; and more! HEALTHCARE FINANCIAL INDUSTRIAL COMPLEX
  • iMBA Inc., OFFICES

    Suite #5901 Wilbanks Drive, Norcross, Georgia, 30092 USA [1.770.448.0769]. Our location is real and we are now virtually enabled to assist new long distance clients and out-of-town colleagues.

  • ME-P Publishing


    If you want the opportunity to work with leading health care industry insiders, innovators and watchers, the “ME-P” may be right for you? We are unbiased and operate at the nexus of theoretical and applied R&D. Collaborate with us and you’ll put your brand in front of a smart & tightly focused demographic; one at the forefront of our emerging healthcare free marketplace of informed and professional “movers and shakers.” Our Ad Rate Card is available upon request [770-448-0769].

  • Reader Comments, Quips, Opinions, News & Updates

  • Start-Up Advice for Businesses, DRs and Entrepreneurs

    ImageProxy “Providing Management, Financial and Business Solutions for Modernity”
  • Up-Trending ME-Ps

  • Capitalism and Free Enterprise Advocacy

    Whether you’re a mature CXO, physician or start-up entrepreneur in need of management, financial, HR or business planning information on free markets and competition, the "Medical Executive-Post” is the online place to meet for Capitalism 2.0 collaboration. Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds. THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
  • OIG Fraud Warnings

    Beware of health insurance marketplace scams OIG's Most Wanted Fugitives at oig.hhs.gov

COVID-19 and Pre-Existing Conditions

Cases Per Condition

[By staff reporters]






Product DetailsProduct DetailsProduct Details


3 Responses


    Some physicians, like Ram Yogendra, MD, MPH strongly believe that COVID-D is not really a “respiratory-lung” disease, but rather a disease
    of hemoglobin pathology. He presents convincing evidence of the hemoglobin failure, because like malaria itself, the virus attacks the hemoglobin molecule directly.

    Other physicians, like Dr. Jaime Lucio Pascual Ballesteros, point to direct evidence of hemoglobinopathy:

    So, has led this some to come to the conclusion that treating this condition like a pulmonary infection is incorrect. And, this has been
    borne out by the failure of ventilation therapy?

    Any thoughts?


    Liked by 1 person

  2. The WHO

    A document posted on the World Health Organization’s website yesterday delivered some disappointing news: Remdesivir, a potential COVID-19 treatment developed by biopharma company Gilead Sciences, did not improve patient outcomes in a randomized clinical trial.

    According to the summary, 13.9% of the patients who received the drug died after one month, versus 12.8% in a control group, the FT and health news site Stat report.

    The twist: The summary was quickly removed from the website. A WHO spokesperson said it was posted by mistake.

    The study, a first-of-its-kind clinical trial in China, was stopped early because it didn’t have enough patients, so Gilead argued its results are inconclusive. Although Gilead did say “trends in the data suggest a potential benefit” for the drug.

    So … what does it all mean?

    Not much—no definitive thumbs up or down for remdesivir yet.
    Several other ongoing studies will hopefully offer more conclusion.



  3. Money Quote:

    Dr. Zhang said, “I would suggest three consecutive negative RT-PCR results to safely discharge, due to high false-negative rate. . .”

    Dr. Jack Lipton, (Department Chair at MSU). . . commented. . ., “The study demonstrates that repeated testing is absolutely necessary. In our clinical trial of university personnel at MSU, we have a young healthy subject with mild symptoms who has tested positive five times over four weeks. People need to realize that a 14-day isolation is appropriate for seeing whether one will develop symptoms after a known exposure to an infected person. Fourteen days is not a sufficient amount of time to be infected, recover and then be virus free.”


    Liked by 1 person

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: